Insider Selling: Galectin Therapeutics (NASDAQ:GALT) Insider Sells 19,442 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 19,442 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $7.04, for a total transaction of $136,871.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Stock Performance

Shares of NASDAQ GALT traded down $1.78 during trading on Friday, hitting $4.38. 4,104,617 shares of the company traded hands, compared to its average volume of 417,051. The firm has a market capitalization of $282.38 million, a price-to-earnings ratio of -7.42 and a beta of 0.95. The business’s fifty day moving average is $5.57 and its 200 day moving average is $4.15. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts predict that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Key Stores Impacting Galectin Therapeutics

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
• Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
• Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
• Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
• Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GALT. Jane Street Group LLC purchased a new stake in shares of Galectin Therapeutics during the 2nd quarter worth approximately $1,580,000. Vivaldi Capital Management LP raised its stake in Galectin Therapeutics by 210.0% in the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock valued at $364,000 after acquiring an additional 116,815 shares during the period. GSA Capital Partners LLP purchased a new stake in Galectin Therapeutics during the third quarter valued at about $369,000. Wealthspire Advisors LLC increased its stake in shares of Galectin Therapeutics by 20.4% in the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after purchasing an additional 81,144 shares in the last quarter. Finally, Truist Financial Corp bought a new position in Galectin Therapeutics in the 2nd quarter worth approximately $143,000. 11.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Galectin Therapeutics has a consensus rating of “Hold” and an average target price of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.